Male and female,
Conditions
Interventions
,Reference (R): EZETROLâ„¢ 10 mg,
Bangkok,
Thailand.
Test (T): Ezetimibe Tablets 10mg. Each tablet contains 10 mg ezetimibe,
,Ezetimibe Tablets 10mg
Sponsors
International Bio Service Co., Ltd.
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1 Healthy Thai male/female subjects between the ages of 18 to 55 years. 2 Body mass index between 18 to 25 kg/m2. 3 Normal laboratory values, including vital signs and physical examination, for all parameters in clinical laboratory tests at screening. Any abnormalities from the normal or reference range will be carefully considered clinically relevant by the physician as individual cases, documented in study files prior to enrolling the subject in this study. 4 Non-pregnant woman (negative pregnancy test) and not currently breast feeding. 5 Female subjects abstain from either hormonal methods of contraception (including oral or transdermal contraceptives, injectable progesterone, progestin subdermal implants, progesterone-releasing IUDs, postcoital contraceptive methods) or hormone replacement therapy for at least 28 days prior to admission in Period 1. Injectable contraceptives e.g. Depo-Provera® will be discontinued at least 6 months prior to admission in Period 1. Subjects agree to use acceptable non-hormonal contraceptive methods such as condom, diaphragm, foams, jellies, or abstinence for at least 14 days prior to admission in Period 1 until 7 days after the end of study. Female subjects of non-childbearing potential must meet at least one of the following criteria prior to admission in Period 1: • Postmenopausal for at least 1 year or • Surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) at least 6 months 6 Male subjects who are willing or able to use effective contraceptive e.g. condom or abstinence after admission in Period 1 until 7 days after the end of study. 7 Have voluntarily given written informed consent (signed and dated) by the subject prior to participating in this study.
Exclusion criteria
Exclusion criteria: 1 History of allergic reaction or hypersensitivity to ezetimibe or to any excipients of tablet 2 History or evidence of clinically significant renal, hepatic including cholelithiasis, gastrointestinal, hematological, endocrine e.g. thyroid, diabetes etc. pulmonary or respiratory e.g. asthma, cardiovascular, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) or any significant ongoing chronic medical illness 3 History or evidence of muscular disease e.g. muscle pain, tenderness, weakness, myopathy or rhabdomyolysis 4 History of problems with swallowing tablets 5 History or evidence of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption 6 History of sensitivity to heparin or heparin-induced thrombocytopenia 7 Any condition possibly affecting drug absorption e.g. gastrectomy, enterectomy, gastritis or duodenal or gastric ulceration other than appendectomy 8 History of preceding diarrhea or vomiting within 24 hours prior to admission in each period 9 History or evidence of drug addict or investigation with urine sample shows a positive test for drug of abuse (morphine, marijuana or methamphetamine) 10 12-lead ECG demonstrating QTc >450 msec, a QRS interval >120 msec or with an abnormality considered clinically significant at screening. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG will be repeated two more times and the average of the three QTc or QRS values will be used to determine the subject’s eligibility. 11 Investigation with blood sample shows positive test for anti-HIV, anti-HCV, VDRL or HBsAg 12 Creatine kinase (CK) levels > 1.5 times of upper normal limit of reference range (unless explained by exercise) at screening laboratory test 13 Abnormal liver function,  1.5 times of upper normal limit of reference range for ALT, AST or bilirubin levels at screening laboratory test 14 History or evidence of habitual use of tobacco or nicotine containing products and cannot abstain for at least 7 days prior to admission and continued until last sample collection in Period 2 15 History or evidence of alcoholism, regular alcohol consumption or alcohol-containing products and cannot abstain for at least 7 days prior to admission in Period 1 and continued until last sample collection in Period 2 16 History or evidence of habitual consume of tea, coffee, xanthine or caffeine containing products and cannot abstain for at least 7 days prior to admission in Period 1 and continued until last sample collection in Period 2 17 Consumption or drinking of grapefruit juice or orange or its supplement/containing products and cannot abstain for at least 7 days prior to admission in Period 1 and continued until last sample collection in Period 2 รับประทานหรืà¸à¸”ื่มน้ำผลไม้จำพวà¸à¹€à¸à¸£à¸Ÿà¸Ÿà¸£à¸¸à¹Šà¸•à¸«à¸£à¸·à¸à¸ªà¹‰à¸¡à¸«à¸£à¸·à¸à¸œà¸¥à¸´à¸•à¸ ัณฑ์เสริมà¸à¸²à¸«à¸²à¸£à¸«à¸£à¸·à¸à¸œà¸¥à¸´à¸•à¸ ัณฑ์ที่มีส่วนประà¸à¸à¸šà¹€à¸«à¸¥à¹ˆà¸²à¸™à¸µà¹‰à¹à¸¥à¸°à¹„ม่สามารถหยุดà¸à¸¢à¹ˆà¸²à¸‡à¸™à¹‰à¸à¸¢ 7 วันà¸à¹ˆà¸à¸™à¹€à¸‚้าพัà¸à¹ƒà¸™à¸£à¸°à¸¢à¸°à¸à¸²à¸£à¸¨à¸¶à¸à¸©à¸²à¸—ี่ 1 à¹à¸¥à¸°à¸•à¹ˆà¸à¹€à¸™à¸·à
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ,Ezetimibe and total ezetimibe plasma concentrations 0,0.25,0.5,0.75,1,1.25,1.5,1.75,2,2.5,3,3.5,4,4.5,5,5.5,6,7,8,9,10,11,12,16,24,36,48,72 hrs post-dos Cmax, AUC0-tlast, AUC0-∞ , | — |
Secondary
| Measure | Time frame |
|---|---|
| Ezetimibe and total ezetimibe plasma concentrations 0,0.25,0.5,0.75,1,1.25,1.5,1.75,2,2.5,3,3.5,4,4.5,5,5.5,6,7,8,9,10,11,12,16,24,36,48,72 hrs post-dos Tmax, t1/2, λz, AUC0-tlast/AUC0-∞, AUC%extrapolate, MRT | — |
Countries
Thailand
Contacts
Public ContactPorranee Puranajoti
International Bio Service Co. Ltd.
Outcome results
None listed